ERBB2 and non-small cell lung carcinoma: The HUDSON study evaluated the efficacy and safety of T-DXd plus durvalumab in NSCLC patients with HER2 overexpression (HER2e) or HER2 mutations (HER2m) whose disease had progressed on prior ICI therapy.